Replies to post #379449 on Anavex Life Sciences Corp (AVXL)

[georgejjl]

It is given that the Anavex Phase 2b/3 Alzheimer's trial cohorts are relatively evenly randomly distributed 1:1:1

170 participants take a high dose 50 mg per day

170 participants take a medium dose 30 mg per day

169 participants take a placebo once per day

**********************************************************************

Anavex's Phase 2b/3 trial for early stage Alzheimer's disease treatment can expect the following:

We can expect approximately 81 super responders who not only better than placebo but actually improved from baseline over time.

We can also expect that approximately 289 of the 340 participants taking Blarcamesine will do better than those on placebo.

Good luck and GOD bless,

[McMagyar]

170 50 Mg super supers
85 30 Mg super supers
255 super supers at baseline or better out of 340 dosed participants!

All 340 dosed participants perform significantly better than SOC or Palexo cohort average..